As with the delivery of any therapeutic agent, there is a need for tissue specificity to optimize uptake, reduce the effective dose, and minimize toxicity associated with off-target side effects. This is especially important when dealing with systemic drug exposure following intravenous administration. Therefore, the Seeker desires novel peptides for the specific targeting of oligonucleotides to cardiac tissue.
This Theoretical Challenge requires only a written proposal.
Nearly 18 million people die every year from cardiovascular diseases worldwide. The human heart is composed of many cells types including cardiomyocytes, fibroblasts, and endothelial cells. Cardiomyocytes are the most abundant and damage to these muscle cells can impair proper heart function and impact efficient blood flow throughout the body. Although non-myocytes occupy a much smaller volume, they play a vital role in maintaining homeostasis and transmitting signals required for cardiomyocyte contraction and survival. Thus, the Seeker desires novel peptides for the specific targeting of oligonucleotides to cardiac tissue, preferably cardiac endothelial cells.
This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.
To receive an award, the Solvers will have to transfer their exclusive Intellectual Property (IP) rights to the Seeker. See the Challenge-Specific Agreement for full details.
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 11, 2018.
Late submissions will not be considered.
ABOUT THE SEEKER
We are an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in Suresnes, France. Since opening our first laboratory in 1954, we have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to provide future generations with a world where quality healthcare is available and accessible to all. Operating in 148 countries, we have 21,000 collaborators employed worldwide and a turnover of 4 billion euros in 2016. Entirely independent, we are able to reinvest 25% of our total revenue (excluding generics) into Research and Development, and all profits are used for further development. Corporate growth at Servier is driven by our continuous pursuit of innovation in five areas of excellence: cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, cancers and diabetes. We are a leading force in cardiology—number 2 in Europe, number 8 worldwide—and oncology has become a top priority in recent years; we also manufacture high-quality generic drugs.
Our three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in our 15 production centres around the world. We have an active partnership policy in the field of biotechnology and we are investing in e-health through our internal WeHealth by Servier initiative. All our employees are driven by shared values and guided by a common vision. Together we share the passion of entrepreneurship and we are committed to therapeutic progress to serve patient needs. For more information, visit: http://www.servier.com/.
What is a Theoretical IP Transfer Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-IP Transfer Challenge, meaning that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. By contrast, Theoretical-Licensing means that the Seeker is requesting non-exclusive rights to use the winning solution. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.